Shopping Cart 0
Cart Subtotal
AED 0

Mylan NV (MYL)-Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Mylan NV (MYL)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mylan NV (Mylan) is a pharmaceutical company, which focuses on development, licensing, manufacture, marketing and distribution of generics, branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, cardiovascular, central nervous systems, infectious disease, oncology, anesthesia and others. Mylan sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. It has operations in the US and Canada, Europe, the Middle East and Africa, and India, Australia, Japan, New Zealand and Brazil. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV Key Recent Developments

Mar 01,2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance

Nov 29,2016: New ADEKplus a Fat Soluble Nutritional Product Launched to Aid Conditions Such as Cystic Fibrosis

Nov 09,2016: Mylan Reports Third Quarter 2016 Results

Aug 25,2016: Teva Plunges After Two U.S. Copaxone Patents Invalidated

Aug 09,2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8%

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Mylan NV-Key Facts 6

Mylan NV-Key Employees 7

Mylan NV-Key Employee Biographies 8

Mylan NV-Major Products and Services 9

Mylan NV-Pharmaceutical Pipeline Products Data 10

Mylan NV, Pipeline Products by Therapy Area 10

Mylan NV, Pipeline Products by Development Phase 10

Mylan NV-History 12

Mylan NV-Company Statement 23

Mylan NV-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Section 2-Company Analysis 31

Mylan NV-Business Description 31

Mylan NV-SWOT Analysis 32

SWOT Analysis-Overview 32

Mylan NV-Strengths 32

Mylan NV-Weaknesses 33

Mylan NV-Opportunities 34

Mylan NV-Threats 35

Mylan NV-Key Competitors 36

Section 3-Company Financial Ratios 37

Financial Ratios-Capital Market Ratios 37

Financial Ratios-Annual Ratios 38

Performance Chart 40

Financial Performance 40

Financial Ratios-Interim Ratios 41

Financial Ratios-Ratio Charts 42

Section 4-Company's Lifesciences Financial Deals and Alliances 43

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 43

Mylan NV, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 44

Mylan NV, Recent Deals Summary 45

Section 5-Company's Recent Developments 46

Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 46

Nov 29, 2016: New ADEKplus a Fat Soluble Nutritional Product Launched to Aid Conditions Such as Cystic Fibrosis 48

Nov 09, 2016: Mylan Reports Third Quarter 2016 Results 49

Aug 25, 2016: Teva Plunges After Two U.S. Copaxone Patents Invalidated 53

Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% 55

Jun 23, 2016: Mylan Donates EUR1 Million to the Princess Maxima Center for Pediatric Oncology 58

May 03, 2016: Mylan Names Kenneth Parks Chief Financial Officer 59

May 03, 2016: Mylan Reports Strong First Quarter 2016 Earnings Results Including Total Revenues Up 17% 60

Feb 22, 2016: Mylan Appoints Anthony Mauro Chief Commercial Officer 62

Feb 22, 2016: Mylan CEO Heather Bresch Elected Chair of Generic Pharmaceutical Association 63

Section 6-Appendix 64

Methodology 64

Ratio Definitions 64

About GlobalData 68

Contact Us 68

Disclaimer 68


List Of Figure

List of Tables

Mylan NV, Key Facts 6

Mylan NV, Key Employees 7

Mylan NV, Key Employee Biographies 8

Mylan NV, Major Products and Services 9

Mylan NV, Number of Pipeline Products by Development Stage 11

Mylan NV, History 12

Mylan NV, Other Locations 25

Mylan NV, Subsidiaries 26

Mylan NV, Key Competitors 36

Mylan NV, Ratios based on current share price 37

Mylan NV 38

Mylan NV (Cont...1) 39

Mylan NV, Interim Ratios 41

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 43

Mylan NV, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 44

Mylan NV, Recent Deals Summary 45

Currency Codes 64

Capital Market Ratios 64

Equity Ratios 65

Profitability Ratios 65

Cost Ratios 66

Liquidity Ratios 66

Leverage Ratios 67

Efficiency Ratios 67


List Of Table

List of Figures

Mylan NV, Pipeline Products by Therapy Area 10

Mylan NV, Pipeline Products by Development Phase 10

Mylan NV, Performance Chart (2012-2016) 40

Mylan NV, Ratio Charts 42

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 43

Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Mylan NV, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Versartis IncTeva Pharmaceutical Industries LtdRegeneron Pharmaceuticals IncPar Pharmaceutical Holdings IncNovartis Pharma AGMerck & Co IncMallinckrodt PlcGlaxoSmithKline PlcEndo International PlcEli Lilly and CompanyBristol-Myers Squibb CompanyAllergan Plc